samedan logo

home > news > detailed info

Theravectys Announces $20M Funding Round


Funding to drive Phase 1 and 1-2 Clinical Trials for COVID-19, HPV induced cancers and HBV Vaccine Candidates

PHILADELPHIA, Penn., February 11, 2021THERAVECTYS, the world leading pioneer in lentiviral vector technology, announced today a fully subscribed $20M funding round. This funding will be used to progress the Theravectys pipeline by driving several vaccine candidates, including their COVID vaccine, into phase 1 and 1-2 clinical trials. These vaccine candidates are based on a proprietary lentiviral vector platform which elicits an unprecedented, efficient cellular immune response through direct in vivo transduction (gene transfer) of dendritic cells.

With a previous HIV clinical phase 1 trial that demonstrated successfully its safety, and several rounds of pre-clinical testing that proved remarkable efficacy, Theravectys looks forward to commencing in-human testing of its vaccines against SARS-CoV2, HPV and HBV (both targeting virus and viro-induced cancers).

“Our goal has always been to deeply transform global health, and this funding helps us to continue on our path,” said Ye Tian, CEO. “Thanks to our pioneering technology, we’re poised to revolutionize immunotherapy and vaccination, changing the way some of the world’s deadliest diseases can be prevented and treated.”

“With proven successes in previous testing, including full eradication of HPV-induced tumors in 100% of mice after a single intramuscular injection, we eagerly anticipate what the next round of clinical tests will bear,” said Christian Brechot, senior scientific advisor. “We now have the opportunity to further test vaccine candidates where we are the most advanced in our preclinical trials, and are quite confident we’ll see successes emerge in our next rounds of clinical trials.”

Theravectys has an extensive patent and IP portfolio based on more than twenty years of research, including exclusive worldwide rights for lentiviral vector production using DNA flap mechanisms. Theravectys’ vectors use the DNA flap technology (cPPT/CTS), developed by Chief Scientist Dr. Pierre Charneau, enabling the virus to cross the nucleus membrane and get into the cell nucleus, so that they can also transfer genes into non-dividing cells, such as dendritic cells.

Theravectys’ lentiviral vectors are engineered for the most efficient expression of the target antigens and elicit appropriate adaptive immune responses in a variety of indications in oncology and virology. They also have a strong proclivity to induce antigenic presentation by dendritic cells, likely the unique cells to mount a proper T cell immune response, by contrast with various other vaccines that do not have a specific targeting of dendritic cells.

Theravectys, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology. Founded by pioneer inventor Dr. Pierre Charneau, as a spin-off of the Institut Pasteur, Theravectys leverages a unique proprietary platform to deliver remarkably safe and highly efficient T-cell vaccines as a response to critical unmet medical needs. Theravectys’ technology and worldwide license domain has an almost unlimited number of applications in infectious diseases, virally-induced cancers and cancers, and is driving a silent revolution in vaccination. Our purpose: ‘profoundly transform global health’. Our approach: strategic industrial partnering for leading our PoC-validated vaccine candidates to clinical trials and to market.

Print this page
Send to a friend
News and Press Releases

Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial of its Janssen COVID-19 Vaccine Candidate

The Phase 3 ENSEMBLE study (NCT04505722) of the single-dose regimen of JNJ-78436735, the investigational vaccine candidate for the prevention of COVID-19 being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, continues to enrol and vaccinate study participants. ENSEMBLE is proceeding to enrol up to 60,000 participants worldwide.1
More info >>

White Papers

Recommendations Sourcing Human Biospecimens


The foundations for protecting human research subjects come from the ethical principles surrounding the Belmont report : Respect for persons, beneficence, and justice. The use of human biospecimens in research supports these principles with legal and ethical regulations - the most important of which is permission.(1) This permission may come directly from the donor or granted by others with authorization to protect the interests of biospecimen donors.
More info >>

Industry Events

DIA Europe 2021

15-19 March 2021, VIRTUAL CONFERENCE

DIA Europe is the must-attend event for all life science professionals working in drug development, from discovery to marketed use. It encourages open collaboration by bringing together representatives from the entire spectrum of the life science landscape and facilitating crucial discussions across several topic tracks: Clinical Development, Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy, and many more.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement